Comprehensive Management of Post-Transplant Diabetes Mellitus: From Intensive Care to Home Care

Endocrinology and Metabolism Clinics of North America

Volumn 36, Issue 4, 2007, Pages 907-922

  Goldberg, Philip A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CYCLOSPORIN; CYTOCHROME P450 3A4; DEXAMETHASONE; GLIBENCLAMIDE; INSULIN; MEGLITINIDE; METFORMIN; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TACROLIMUS; TROGLITAZONE;

CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES CONTROL; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG EFFICACY; GLUCONEOGENESIS; GLUCOSE TOLERANCE; HEADACHE; HOME CARE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTENSIVE CARE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIPOGENESIS; MONOTHERAPY; MULTIPLE REGRESSION; NAUSEA; NUCLEIC ACID SYNTHESIS; OUTPATIENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

DIABETES MELLITUS; HOME CARE SERVICES; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOSUPPRESSION; INSULIN; INTENSIVE CARE; ORGAN TRANSPLANTATION;

EID: 35649020199     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2007.07.011     Document Type: Review

References (74)

1. Viberti G. Diabetes mellitus: a major challenge in transplantation. Transplant Proc 33 Suppl 5A (2001) 3S-7S
2. Woo M., Przepiorka D., Ippoliti C., et al. Toxicities of tacrolimus and cyclosporine A after allogeneic blood stem cell transplantation. Bone Marrow Transplant 20 (1997) 1095-1098
3. Reisaeter A.V., and Hartmann A. Risk factors and incidence of posttransplant diabetes mellitus. Transplant Proc 33 Suppl 5A (2001) 8S-18S
4. Jindal R.M., and Hjelmesaeth J. Impact and management of posttransplant diabetes mellitus. Transplantation 70 Suppl (2000) SS58-SS63
5. Kasiske B.L., Guijarro C., Massy Z.A., et al. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 7 (1996) 158-165
6. Lindholm A., Albrechtsen D., Frodin L., et al. Ischemic heart disease-major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 60 (1995) 451-457
7. Ojo A.O., Hanson J.A., Wolfe R.A., et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 57 (2000) 307-313
8. Markovitz L.J., Wiechmann R.J., Harris N., et al. Description and evaluation of a glycemic management protocol for patients with diabetes undergoing heart surgery. Endocr Pract 8 (2002) 10-18
9. Miles A.M.V., Nabil S., Horowitz R., et al. Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes?. Transplantation 65 (1998) 380-384
10. Chilcott J.B., Whitby S.M., and Moore R. Clinical impact and health economic consequences of posttransplant type 2 diabetes mellitus. Transplant Proc 33 Suppl 5A (2001) 32S-39S
11. Ekstrand A.V., Eriksson J.G., Gronhagen-Riska C., et al. Insulin resistance and insulin deficiency in the pathogenesis of posttransplant diabetes in man. Transplantation 53 (1992) 563-569
12. Midtvedt K., Hartmann A., Hjelmesaeth J., et al. Insulin resistance is a common denominator of post-transplant diabetes mellitus and impaired glucose tolerance in renal transplant recipients. Nephrol Dial Transplant 13 (1998) 427-431
13. Nam J.H., Mun J.I., Kim S.I., et al. B-cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation 71 (2001) 1417-1423
14. Hagen M., Hjelmesaeth J., Jenssen T., et al. A 6-year prospective study on new onset diabetes mellitus, insulin release and insulin sensitivity in renal transplant recipients. Nephrol Dial Transplant 18 (2003) 2154-2159
15. Weir M. Impact of immunosuppressive regimens on posttransplant diabetes mellitus. Transplant Proc 33 Suppl 5A (2001) 23S-26S
16. Montori V.M., Basu A., Erwin P.J., et al. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 25 (2002) 583-592
17. Meachem L.R., Abdul-Latif H., Sullivan K., et al. Predictors of change in insulin sensitivity during glucocorticoid treatment. Horm Metab Res 29 (1997) 172-175
18. Hjelmesaeth J., Hartmann A., Kofstad J., et al. Glucose intolerance after renal transplantation depends on prednisolone dose and recipient age. Transplantation 64 (1997) 979-983
19. Van Hooff J.P., Christians M.H.L., and van Duijnhoven E.M. Evaluating mechanisms of post-transplant diabetes mellitus. Nephrol Dial Transplant 19 Suppl 6 (2004) vi8-vi12
20. Knoll G.A., and Bell R.C. Tacrolimus versus cyclosporine for immunosuppression in renal transplantation: meta-analysis of randomized trials. BMJ 318 (1999) 1104-1107
21. Heisel O., Heisel R., Balshaw R., et al. New-onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 4 (2004) 583-595
22. Zerr K.J., Furnary A.P., Grunkemeier G.L., et al. Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann Thorac Surg 63 (1997) 356-361
23. Pomposelli J.J., Baxter III J.K., Babineau T.J., et al. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. J Parenter Enteral Nutr 22 (1998) 77-81
24. Umpierrez G.E., Isaacs S.D., Bazargan N., et al. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 87 (2002) 978-982
25. Furnary A.P., Zerr K.J., Grunkmeier G.L., et al. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 67 (1999) 352-362
26. Furnary A.P., Gao G., Grunkemeier G.L., et al. Continuous insulin infusion reduces mortality in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 125 (2003) 1007-1021
27. Van den Berghe G., Wouters P., Weekers F., et al. Intensive insulin therapy in critically ill patients. N Engl J Med 345 (2001) 1359-1367
28. Cheung N.W., Wong V.W., and McLean M. The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care 29 (2006) 765-770
29. Van den Berghe G., Wilmer A., Hermans G., et al. Intensive insulin therapy in the medical ICU. N Engl J Med 354 (2006) 449-461
30. Van den Berghe G., Wilmer A., Milants I., et al. Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm. Diabetes 55 (2006) 3151-3159
31. Clement S., Braithwaite S.S., Magee M.F., et al., On behalf of the Diabetes in Hospitals Writing Committee. Diabetes Care 27 (2004) 553-591
32. American College of Endocrinology Task Force on Inpatient Diabetes and Metabolic Control. American College of Endocrinology position statement on inpatient diabetes and metabolic control. Endocr Pract 10 (2004) 77-82
33. DeSantis A.J., Schmeltz L.R., Schmidt K., et al. Inpatient management of hyperglycemia: the Northwestern experience. Endocr Pract 12 (2006) 491-505
34. Goldberg P.A., Siegel M.D., Sherwin R.S., et al. Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit. Diabetes Care 27 (2004) 461-467
35. Goldberg P.A., Roussel M.G., and Inzucchi S.E. Clinical results of an updated insulin infusion protocol in critically ill patients. Diabetes Spectrum 18 (2005) 188-191
36. Goldberg P.A., and Inzucchi S.E. Selling root canals: lessons learned from implementing a hospital insulin infusion protocol. Diabetes Spectrum 18 (2005) 28-33
37. Markell M. Clinical impact of posttransplant diabetes mellitus. Transplant Proc 33 Suppl 5A (2001) 19S-22S
38. Trence D.L., Kelly J.L., and Hirsch I.B. The rationale and management of hyperglycemia for in-patients with cardiovascular disease: time for change. J Clin Endocrinol Metab 88 (2003) 2430-2437
39. Bode B.W., Braithwaite S.S., Steed R.D., et al. Intravenous insulin therapy: indications, methods, and transition to subcutaneous insulin therapy. Endocr Pract 10 Suppl 2 (2004) 71-80
40. Abern M., Boland E., Rothenberg D.M., et al. Intensive insulin therapy (IIT) after coronary artery bypass graft (CABG) surgery: from latest IV infusion rate, provide 8 times rate as NPH insulin plus 4 times rate as regular insulin. [abstract]. Diabetes 53 suppl 2 (2004) A116
41. Inzucchi S.E. Clinical practice: management of hyperglycemia in the hospital setting. N Engl J Med 355 (2006) 1903-1911
42. Hirsch I.B. Drug therapy: insulin analogues. N Engl J Med 352 (2005) 174-183
43. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
44. United Kingdom Prospective Diabetes Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
45. United Kingdom Prospective Diabetes Group. Tight blood pressure control and risk of macrovascular complications in type 2 diabetes (UKPDS 38). BMJ 317 (1998) 703-713
46. Hjelmesaeth J., Jenssen T., and Hartmann A. Diagnosing PTDM. [letter]. Transplantation 75 (2003) 1761
47. Davidson J., Wilkinson A., Dantal J., et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Transplantation 75 suppl (2003) SS3-SS24
48. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care 30 Suppl 1 (2007) S4-S41
49. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 30 Suppl 1 (2007) S42-S47
50. Shah A., Kendall G., Demme R.A., et al. Home glucometer monitoring markedly improves diagnosis of post renal transplant diabetes mellitus in renal transplant recipients. Transplantation 80 (2005) 775-781
51. Hoban R., Gielda B., Temkit M., et al. Utility of HbA1c in the detection of subclinical post renal transplant diabetes. Transplantation 81 (2006) 379-383
52. Sherwin R.S. Diabetes mellitus. In: Arend W.P., Armitage J.O., and Drzaen J.M. (Eds). Cecil textbook of medicine. 22nd edition (2004), W.B. Saunders, Philadelphia
53. Kirpichnikov D., MacFarlane S.I., and Sowers J.R. Metformin: an update. Ann Intern Med 137 (2002) 25-33
54. Baldwin Jr. D., and Duffin K.E. Rosiglitazone treatment of diabetes mellitus after solid organ transplantation. Transplantation 77 (2004) 1009-1014
55. Villaneuva G., and Baldwin D. Rosiglitazone therapy of posttransplant diabetes mellitus. Transplantation 80 (2005) 1402-1405
56. Del Prato S., Aragona M., and Copelli A. Sulfonylureas and hypoglycaemia. Diabetes Nutr Metab 15 (2002) 444-450
57. Willi S.M., Kennedy A., Wallace P., et al. Troglitazone antagonizes metabolic effects of glucocorticoids in humans. Diabetes 51 (2002) 2895-2902
58. Willi S.M., Kennedy A., Brant B.P., et al. Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes. Diabetes Res Clin Pract 58 (2002) 87-96
59. Fujibayashi K., Nagasaka S., Itabashi N., et al. Troglitazone efficacy in a subject with glucocorticoid-induced diabetes. Diabetes Care 22 (1999) 2088-2089
60. Pietruck F., Kribben A., Van T.N., et al. Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation. Transpl Int 18 (2005) 483-486
61. Voytovich M.H., Simonsen C., Jenssen T., et al. Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients. Nephrol Dial Transplant 20 (2005) 413-418
62. Blickle J.F. Meglitinide analogues: a review of clinical data focused on recent trials. Diabetes Metab 32 (2006) 113-120
63. Pasternak J.J., McGregor D.G., and Lanier W.L. Effect of single-dose dexamethasone on blood glucose concentration in patients undergoing craniotomy. J Neurosurg Anesthesiol 16 (2004) 122-125
64. Boots J.M.M., Van Duijnhoven E.M., Christiaans M.H.L., et al. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 13 (2002) 221-227
65. Hjelmesaeth J., Hartmann A., Kofstad J., et al. Tapering off prednisolone and cyclosporine the first year after renal transplantation: the effect on glucose tolerance. Nephrol Dial Transplant 16 (2001) 829-835
66. Midtvedt K., Hjelmesaeth J., Hartmann A., et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol 15 (2004) 3233-3239
67. Scantlebury V., Shapiro R., Fung J., et al. Transplant Proc 23 (1991) 3169-3170
68. Kanzler S., Lohse A.W., Schirmacher P., et al. Complete reversal of FK 506 induced diabetes in a liver transplant recipient by change of immunosuppression to cyclosporine A. Z Gastroenterol 34 (1996) 128-131
69. Lagget M., Marzano A., Actis G.C., et al. Disappearance of diabetes mellitus after conversion from FK 506 to Neoral in two liver transplant patients. Transplant Proc 30 (1998) 1863-1865
70. Emre S., Genyk Y., Schluger L.K., et al. Treatment of tacrolimus-related adverse events by conversion to cyclosporine in liver transplant recipients. Transpl Int 13 (2000) 73-78
71. Hjelmesaeth J., Hartmann A., Midtvedt K., et al. Metabolic syndrome after renal transplantation. Nephrol Dial Transplant 16 (2001) 1047-1052
72. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
73. Chobanian A.V., Bakris G.L., Black H.R., et al., the National High Blood Pressure Education Program Writing Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
74. Grundy S.M., Cleeman J.I., Merz C.N.B., et al., for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239